Bartunek, J. Terzic, A. Davison, B.A. Filippatos, G.S. Radovanovic, S. Beleslin, B. Merkely, B. Musialek, P. Wojakowski, W. Andreka, P. Horvath, I.G. Katz, A. Dolatabadi, D. El Nakadi, B. Arandjelovic, A. Edes, I. Seferovic, P.M. Obradovic, S. Vanderheyden, M. Jagic, N. Petrov, I. Atar, S. Halabi, M. Gelev, V.L. Shochat, M.K. Kasprzak, J.D. Sanz-Ruiz, R. Heyndrickx, G.R. Nyolczas, N. Legrand, V. Guédès, A. Heyse, A. Moccetti, T. Fernandez-Aviles, F. Jimenez-Quevedo, P. Bayes-Genis, A. Hernandez-Garcia, J.M. Ribichini, F. Gruchala, M. Waldman, S.A. Teerlink, J.R. Gersh, B.J. Povsic, T.J. Henry, T.D. Metra, M. Hajjar, R.J. Tendera, M. Behfar, A. Alexandre, B. Seron, A. Stough, W.G. Sherman, W. Cotter, G. Wijns, W., Cardiopoietic cell therapy for advanced ischaemic heart failure: Results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial, EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, (38), 648-660, 2017, Oxford University Press,